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The effective prescription of antibiotics for the bacterial biofilms present within the
lungs of individuals with cystic fibrosis (CF) is limited by a poor correlation between
antibiotic susceptibility testing (AST) results using standard diagnostic methods (e.g.,
broth microdilution, disk diffusion, or Etest) and clinical outcomes after antibiotic
treatment. Attempts to improve AST by the use of off-the-shelf biofilm growth platforms
show little improvement in results. The limited ability of in vitro biofilm systems to mimic
the physicochemical environment of the CF lung and, therefore bacterial physiology
and biofilm architecture, also acts as a brake on the discovery of novel therapies for
CF infection. Here, we present a protocol to perform AST of CF pathogens grown as
mature, in vivo-like biofilms in an ex vivo CF lung model comprised of pig bronchiolar
tissue and synthetic CF sputum (ex vivo pig lung, EVPL).
Several in vitro assays exist for biofilm susceptibility testing, using either standard
laboratory medium or various formulations of synthetic CF sputum in microtiter plates.
Both growth medium and biofilm substrate (polystyrene plate vs. bronchiolar tissue)
are likely to affect biofilm antibiotic tolerance. We show enhanced tolerance of clinical
Pseudomonas aeruginosa and Staphylococcus aureus isolates in the ex vivo model;
the effects of antibiotic treatment of biofilms is not correlated with the minimum
inhibitory concentration (MIC) in standard microdilution assays or a sensitive/resistant
classification in disk diffusion assays.
The ex vivo platform could be used for bespoke biofilm AST of patient samples and
as an enhanced testing platform for potential antibiofilm agents during pharmaceutical
research and development. Improving the prescription or acceleration of antibiofilm
drug discovery through the use of more in vivo-like testing platforms could drastically
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improve health outcomes for individuals with CF, as well as reduce the costs of clinical
treatment and discovery research.
Introduction
Chronic biofilm infections affect individuals whose normal
immune defenses are compromised. Groups at risk include
those with the genetic condition cystic fibrosis (CF)1 .
Colonization of the abnormally thick, adhesive mucus in the
respiratory tract in early infancy leads to intractable biofilm
infections of the bronchioles2,3 . The growth of bacteria
as extensive matrix-encapsulated biofilms is one factor
that distinguishes chronic infections of immunocompromised
people from acute infections of healthy hosts and the biofilm
state both protects bacteria from antibiotic exposure (due to
reduced diffusion through the matrix) and decreases their
antibiotic susceptibility (e.g., through induction of quiescence
or upregulation of efflux pumps)4,5 . However, disease-
specific alterations in host tissue physiology and chemistry
further alter bacterial physiology from that observed in acute
infections or in standard laboratory growth conditions. Key
examples in CF include the use of unusual carbon sources,
such as fatty acids and amino acids released from lung
surfactant and produced by microbial degradation of mucin,
the release of micronutrients, such as iron from damaged
tissues, and microaerobiosis6,7 ,8 .
The specific physicochemical conditions in a particular
biofilm infection context can therefore influence responses to
antibiotics. First, the structure and depth of the extracellular
matrix depends on local environmental conditions, such as
nutrients or shear forces. Second, environmental cues can
trigger expression of specific antibiotic resistance genes.
For example, the CF pathogen Pseudomonas aeruginosa
shows increased expression of a beta-lactamase and
reduced expression of porins in CF sputum versus in vitro9 ,
while another CF pathogen, Burkholderia cenocepacia,
upregulates beta-lactamases and efflux pumps when
grown in CF sputum10 . Third, in-host conditions can
cue a physiological or genetic switch to antibiotic-tolerant
phenotypes, which are hard to recapitulate in vitro.
These include small colony variants of the CF pathogen
Staphylococcus aureus11,12 .
All of these data indicate that when diagnostic labs isolate
individual clones from pathogenic biofilm and perform AST on
planktonic or agar-plate grown cultures in standard laboratory
media (broth microdilution, disk diffusion or Etest), the results
often do not predict which antibiotics will actually work in
vivo. Even if in vitro biofilm assays are used, they may not
cue an in vivo-like biofilm phenotype due to differences in
the medium and attachment surface used, so assays using
flow cells or high-throughput microplate platforms can over-
estimate antibiotic sensitivity13 . The same problem applies
to researchers in academia and industry seeking to develop
new antibiofilm agents: testing drug potential using in vitro
platforms like flow cells, microtiter plates, or Center for
Disease Control biofilm reactors may set the biofilm efficacy
bar too low and produce false positives in the research,
development pipeline.
The poor correlation between AST results and clinical
outcome after antibiotic treatment in CF is well known. Many
clinicians simply ignore diagnostic lab AST as there are no
uniform, CF-specific guidelines for interpreting these results
and instead make case-by-case decisions for prescribing.
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Attempts have been made to improve CF AST by using
the Calgary biofilm device, which uses biofilms grown
on the surface of plastic pegs set within the wells of a
microplate containing standard AST medium (e.g., cation-
adjusted Muller-Hinton broth)14,15 . This assay does no
better at predicting which antibiotics will work in vivo than
standard planktonic AST16 . The impact on patients with CF
is stark. Despite repeated antibiotic administration (regular
inhaled antibiotics and a median of 27 days/year receiving
intravenous antibiotics for individuals with CF in the United
Kingdom)17 , frequent and unpredictable episodes of acute
pulmonary exacerbation lead to progressive lung damage
and, in approximately 90% of cases, death from respiratory
failure. In a recent analysis, bacterial lung infection was the
strongest predictor of medication costs in CF, adding on
average €3.6K/patient/year to direct healthcare costs18,19 .
For acute infections of otherwise healthy individuals, current
research and policy focusing on rapid AST based on, for
example, point-of-care genomic prediction is ideal20 . But
in the case of chronic CF infections, it is clear that a
different approach is needed: the implementation of AST in
host-mimicking models that better recapitulate the in vivo
environment and pathogen metabolic state and allow for the
formation of realistic biofilm structure.
We have previously developed a CF biofilm model that
comprises sections of pig bronchiole incubated in synthetic
CF sputum and infected with P. aeruginosa or S. aureus.
Uninfected EVPL retains normal histopathology for 7 days
but lab or clinical isolates of P. aeruginosa and S. aureus
reproducibly form in vivo-like aggregates around the tissue,
mimicking the etiology of CF infection21,22 ,23 . We present
a protocol for using this high-validity, high-throughput model
as a tailored biofilm AST platform for CF and present
exemplary results showing the high tolerance of pathogen
biofilms to clinically-used antibiotics when grown in the model.
The model could readily be incorporated into research,
development pipelines for the management or prevention of
biofilm formation and potentially into diagnostic AST. Most
equipment used (see Table of Materials) may readily be found
in a typical microbiology laboratory, although a bead beater
is essential, and we have found from work with collaborators
that a suitable ultraviolet germicidal cabinet may also need
to be procured. As the lungs are sourced from commercial
butchers or abattoirs, the model presents no ethical concerns.
Protocol
This protocol uses pig lungs sourced from a commercial
abattoir that supplies meat for human consumption. Under UK
legislation, using leftover tissue from animals slaughtered for
meat does not require ethical approval; we advise readers to
check relevant local laws and institutional guidelines before
starting work.
1. Preparation of Synthetic CF Sputum Media
(SCFM)
1. To make SCFM for use with EVPL tissue, follow the
recipe outlined by Palmer et al.24  with the modification
that glucose is removed from the recipe.
 
NOTE: Palmer et al.'s recipe contains free amino
acids, cations, anions and lactate at concentrations
representative of the average concentrations found in
a selection of sputum samples from CF patients. It
has been shown to cue comparable carbon-usage
pathways and expression of quorum sensing signals by
P. aeruginosa PA14 to growth in medium made from
lyophilised patient sputum24 . A recipe for 1 L modified
SCFM is supplied in Table S1.
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2. Filter sterilize the SCFM immediately after preparation
and store at 4 °C for up to 1 month.
2. Dissection and infection of ex vivo pig lung
(EVPL) tissue
1. Prior to dissection, prepare an agar plate/s of required
bacterial strain/s for infection using whatever agar is
standard in the lab for P. aeruginosa/S. aureus (e.g.,
lysogeny broth + 1.2% agar).
2. Calculate how many porcine bronchiolar tissue pieces
are required for the experiment, including uninfected
control tissue pieces. Multiply this number by two to
repeat the experiment in two replicate lungs to confirm
repeatability of results.
3. Multiply the total number of tissue pieces required by 0.5
to determine the volume of SCFM agarose (mL) needed
to make agarose pads to make enough medium for 400
µL/tissue piece plus spare SCFM agar to account for any
pipetting errors or evaporation during preparation.
4. Add 0.12 g of agarose to every 15 mL of SCFM required
to make the desired total volume of SCFM with 0.8%
weight/volume agarose.
5. Heat the SCFM agarose solution until the agarose is
fully dissolved. A domestic microwave on low power
is recommended. The time required depends on the
wattage of the microwave. Allow the agarose to cool to
approximately 50 °C (warm to the touch but comfortable
to hold). Do not allow to cool any further.
6. Using a pipette, add 400 µL of the SCFM agarose to one
well of a 24-well plate per tissue piece needed.
7. Sterilize the SCFM agarose-containing 24-well plate/s
under ultraviolet light for 10 min.
8. Prepare three replicate washes for every intact lung
being dissected using 20 mL of sterile Dulbecco's
modified Eagle medium (DMEM) plus 20 mL of
sterile Roswell Park Memorial Institute (RPMI) 1640
supplemented with 50 µg/mL ampicillin.
9. Make an aliquot of 40 mL SCFM as a final wash for every
intact lung being dissected. All washes can be stored
overnight at 4 °C or used immediately.
10. Obtain lungs from the designated source as soon as
possible after slaughter, ensuring they are kept cold by
transporting to the laboratory in a domestic coolbox.
 
NOTE: Lungs closer to the day of slaughter show less
bruising from storage, but tissue kept on cold storage
for up to 4 days from slaughter can also be used. As
the coolbox needs to be taken into the butcher's shop
or abattoir, it must be decontaminated following local
lab guidelines after each use and stored outside the
microbiology lab when not in use, to reduce the risk of
contamination and a breach of containment.
11. Working on a sterilized surface and under a flame, place
the lungs on a clean plastic chopping board covered with
autoclaved aluminum foil. Check that the bronchioles
remain intact. If there has been any damage at the
abattoir or during transport the lungs are not suitable for
use.
12. Heat a palette knife under a flame and very briefly
touch the knife to the area of the lung surrounding the
bronchiole to sterilize the surface of the tissue.
13. Cut away the surface tissue surrounding the bronchiole
using a sterile mounted razor blade. Make incisions
parallel to the bronchiole to prevent any damage.
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14. Once the bronchiole has been exposed, make a cross-
sectional incision through the bronchiole at the highest
point visible to free the bronchiole.
15. Using sterile forceps, lightly hold the free end of the
bronchiole and cut away any remaining unwanted tissue
using a sterile mounted razor blade. Make a final
cross-sectional incision across the bronchiole before any
branching is visible to remove the bronchiole from the
lungs.
16. Place the bronchiole in the first DMEM/RPMI 1640 wash.
Leave the bronchiole in the wash and repeat steps
2.11-2.14 to harvest additional sections of bronchiole
from the same lung as required to yield sufficient tissue
sections for the planned experiment.
17. Place any additional bronchiolar sections from the same
lung into the wash (step 2.16). Leave in the wash for at
least 2 min.
18. Remove the bronchioles from the first DMEM/RPMI 1640
wash and place the samples in a sterile Petri dish.
19. Hold each bronchiole lightly using sterile forceps, making
sure not to damage the tissue. Remove as much
remaining soft tissue as possible and cut the tissue into
~5 mm wide strips using sterile dissection scissors.
20. Place all of the bronchiolar tissue strips into the second
DMEM/RPMI 1640 wash. Leave in the wash for at least
2 min.
21. Remove the tissue strips from the second wash using
sterile forceps, taking care not to damage the tissue.
Place the tissue in a clean, sterile Petri dish.
22. Remove any remaining soft tissue attached to the
bronchiole and cut the strips into squares (~5 mm x 5
mm) using sterile dissection scissors.
23. Add the third DMEM/RPMI 1640 wash into the Petri dish.
Lightly mix the tissue pieces in the wash by swirling the
dish.
24. Pour the third wash out of the Petri dish without removing
the tissue pieces.
25. Add the final SCFM wash to the tissue-containing Petri
dish, ensuring that all of the tissue pieces are covered.
26. Sterilize the tissue pieces in SCFM under UV light for 5
min.
27. Use sterile forceps to transfer each sterilized bronchiolar
tissue piece into individual wells of a 24-well plate/s
containing SCFM agarose pads.
28. To infect each tissue piece with the desired bacterial
strain, touch a colony grown on an agar plate with the
tip of a 29 G needle attached to a sterile 0.5 mL insulin
syringe. Then touch the colony onto the tissue piece,
gently pricking the tissue surface.
 
NOTE: Using an insulin syringe equipped with a 29
G needle allows the needle to be held accurately and
comfortably while keeping fingers a safe distance from
the both needle and lung tissue. It is possible to perform
this step using 29 G needles that are not attached to a
syringe, but this requires greater dexterity and increases
the risk of a needlestick injury. Insulin syringes are readily
available.
29. For the uninfected controls, gently prick the surface of
each of the tissue piece with the tip of a 29 G needle
attached to a sterile 0.5 mL insulin syringe.
30. Use a pipette to add 500 µL of SCFM to each well.
31. Sterilize a breathable sealing membrane for each 24-
well plate under ultraviolet light for 10 min (Table of
Materials).
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32. Remove the lid/s from the 24-well plate/s and replace
with the breathable membrane.
33. Incubate the plates at 37 °C for the desired incubation
(infection) time without shaking. Check that there is
no visible growth of the inoculated pathogen on the
uninfected control pieces (contamination control).
 
NOTE: If desired, ampicillin may be added to the SCFM
agarose pads in step 2.5 and covering SCFM in step 2.30
to a final concentration of 20 µg/mL. This will suppress
the growth of most endogenous bacteria on the lungs
without affecting P. aeruginosa or S. aureus growth but,
as the presence of ampicillin may affect susceptibility to
other antibiotics, the reader is left to make this choice
depending on the strains and antibiotics they wish to test.
3. Determination of antibiotic efficacy
NOTE: A schematic detailing the steps of this assay is
provided in Figure S1.
1. To measure antibiotic tolerance of biofilms formed on
EVPL, replicate sets of lung pieces, from at least two
independent lungs, must be set up during the dissection
and infection. One set of pieces is required for a negative
control (no antibiotic treatment), and one set is required
for each concentration of antibiotic to be tested.
2. After 48 hours of incubation, visually inspect the
uninfected tissue pieces. Some growth of bacteria
endogenous to the pig lung may have occurred, leading
the SCFM around these sections to be turbid. If growth
typical of the selected study species are observed (e.g.,
blue-green pigmentation diagnostic of P. aeruginosa), re-
start the experiment with fresh lungs.
3. If the uninfected tissue sections show no or only minimal
bacterial growth, prepare one 24-well wash plate and one
24-well treatment plate, each containing 500 µL of fresh
SCFM without antibiotics or with the antibiotic of interest
per well per lung tissue piece.
4. Remove each infected tissue piece from the incubation
plate with flame sterilized forceps, swirl briefly in a
fresh well of the wash plate to remove any non-biofilm
associated bacterial cells, and transfer to the appropriate
well of the treatment plate.
5. Seal the treatment plates with fresh breathable
membrane.
6. Incubate the treatment plate/s at 37 °C without shaking
for 18-24 h.
7. Using flame sterilized forceps, remove each lung piece
from the 24-well plate and put in a sterile 2 mL
homogenization tube containing 1 mL of phosphate-
buffered saline (PBS) and 1 g of metal beads (Table of
Materials).
8. Bead beat for 40 seconds at 4 m/s.
 
NOTE: Bead beating with the specific beads and
homogeniser suggested in the Table of Materials does
not cause significant lysis of bacteria, but each lab
using the protocol should check the effects of their
chosen beads and homogeniser prior to commencing
AST assays.
9. Serially dilute the lung homogenate using PBS and
plate on Lysogeny Broth (LB) agar to determine the
colony forming units (CFU) in individual untreated and
antibiotic-treated tissue pieces according to standard
plating methods.
 
NOTE: Optional: Prepare duplicate plates on selective
media to confirm colony identities; e.g., using mannitol
salt agar for S. aureus.
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Representative Results
The EVPL model provides a high throughput assay platform,
making it possible to screen a large number of bacterial
isolates for antibiotic susceptibility at one time (Figures 1
and 2) or to screen strains against a range of antibiotic
concentrations in one experiment (Figure 3). With practice,
we have found that approximately 200 bronchiolar tissue
sections can be prepared from lungs in 2 hours. The
entire experiment for AST can be completed within normal
working hours. Growth of Pseudomonas aeruginosa and
Staphylococcus aureus isolates and the establishment of 48 h
biofilm in the model is reliable and, when monitored by viable
cell count, produces consistent bacterial loads (Figures 1
and 2). Images of tissue-associated biofilms of Pseudomonas
aeruginosa and Staphylococcus aureus grown in EVPL
may be found, along with protocols for preparation for light
microscopy and histological staining, in our publications21,23 .
However, the reproducibility of CFU counts varies for different
bacterial species. This can be quantified using standard
repeatability calculations after ANOVA25 ; we have found that
there is typically greater variation between CFU in replicate
lung samples for S. aureus than for P. aeruginosa. We
recommend that, on adoption of the model by a laboratory,
repeat calculations are conducted on pilot experiments to
optimize experimental techniques and to determine samples
sizes to be used in final experiments (an example of this may
be found in the data supplement for Sweeney et al26 ).
When grown in the EVPL, biofilms of P. aeruginosa and
S. aureus demonstrate increased tolerance to antibiotics
compared to susceptibility in standard, industry approved
broth MIC (Figure 1) and disc assays using standard media
(Figure 2). The various effects of different antibiotics on
EVPL established biofilm are distinguishable, for example
P. aeruginosa killing is achieved in EVPL with 4-16X MIC
ciprofloxacin but not with 4-8X MIC chloramphenicol (Figure
1). A twice daily dose of 600 mg linezolid achieves a serum
concentration above the MIC90 for susceptible pathogens
(4 µg/mL)27  and is regarded as adequate exposure without
adverse side effects28 . Data presented in Figure 2 shows
that S. aureus populations, susceptible to linezolid in the disc
assay, are able to survive target serum concentrations, and
higher (12 µg/mL), in EVPL. There is no clear correlation
between MIC and antibiotic effects on EVPL-grown biofilms
for P. aeruginosa (Figure 1). Gaining a more accurate
measure of in vivo antibiotic tolerance is important because
sub-optimal dosing of antibiotics could increase the risk of
selection for resistance in chronic infection.
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It is well known that the biofilm mode of growth can
significantly reduce bacterial susceptibility to antibiotics. This
has led to the development of many in vitro biofilm assays
and the use of minimum biofilm eradication concentration
(MBEC)14,15  instead of MIC as a more accurate predictor of
susceptibility in chronic infection. The use of SCFM (in varying
formulations) has also been recommended for use in MIC or
MBEC testing29 . Here we show that even an optimized in vitro
assay cannot accurately predict P. aeruginosa susceptibility
to colistin in the EVPL. The amount of antibiotic required
to achieve 3 log10 killing of EVPL-grown bacteria is often
significantly higher than the MIC or the MBEC calculated from
standard in vitro assays, even when SCFM is used for these
assays (Figure 3). This is consistent with a Cochrane review
that reported that current implementations of in vitro biofilm
susceptibility testing do not provide any increased predictive
power for antibiotic prescribing in CF compared to standard
susceptibility testing16 .
It is also simple to use the model to assess the impact
of antibiotics on biofilm bacteria over time, as sufficient
replica pieces of lung can be inoculated to allow destructive
sampling. In addition to distinguishing differences between
antimicrobial agents, the model can highlight changes in
susceptibility at different bacterial growth stages or age of
biofilm and for different antibiotic dosing intervals. Figure 4
illustrates the increasing tolerance of P. aeruginosa biofilms to
meropenem as they mature. This could be useful to determine
the efficacy of novel agents, for example whether they are
more effective during rapid cell division. It may also be
an important consideration when setting the constraints of
an experiment, as it may be necessary to standardize and
validate biofilm age to avoid the age having an influence on
results.
In Figure 5, S. aureus survival was measured at 4 h and
24 h post exposure to flucloxacillin and it was possible to
observe differences in the reduction for bacterial cell counts
across time and between isolates. This may be useful for drug
development, for instance when defining pharmacokinetic
and pharmacodynamic parameters or when elucidating the
mode of action of a novel agent.
Variations in bacterial load often increase with extended
culture times. This can be seen in the untreated control in
Figure 5 following 48 h biofilm development and a further 24
h exposure to account for antibiotic dosing interval. Variation
is intrinsic to the model; each lung sample is independent
from others and reflects the natural variation of lungs. It is,
therefore, important to ensure that a sufficient number of
replicates is included to allow for validation and an accurate
interpretation of results. We refer the reader back to our
recommendation to conduct repeat calculations on the data
to enable the selection of robust sample sizes.
For simplicity, we have presented representative data taken
from replicate tissue sections acquired from a single pair of
lungs in each experiment, but in practice it is necessary to
perform repeat experiments on tissue sections taken from
replicate animals. This should be done in order to account
for any biological variation between individual pigs, and we
refer the reader to our published work for examples of
how consistent the results can be between tissues taken
from replicate pigs and how this variation is accounted for
in statistical analysis of data using analysis of variance
(ANOVA)/general linear models (GLM)21,26 .
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Figure 1. Total CFU of 11 CF Pseudomonas aeruginosa clinical isolates recovered from the EVPL model following
treatment with antibiotics. Representative results of antibiotic treatment of P. aeruginosa in the EVPL model. Each
strain was grown on EVPL tissue for 48 h then transferred to antibiotic (triangles) or PBS as a control (circles) for 18 h and
the CFU/lung determined. The MIC for the appropriate antibiotic determined in standard cation-adjusted MHB is shown
in brackets next to each strain (x-axis). The strains are ordered by increasing MIC values. Data were analyzed using t-
tests when appropriate and Mann-Whitney U tests for non-parametric datasets. Significant differences between antibiotic
treated and untreated tissues are denoted by asterisks (P < 0.05). A. Recovered viable counts from P. aeruginosa biofilms
grown in the EVPL model and treated with 64 µg/mL chloramphenicol (highest MIC value recorded). For each isolate, the
standardized mean difference in CFU between chloramphenicol-treated and untreated tissue sections was calculated using
Cohen's d. There was no correlation between MIC value in the standard test and the decrease in viable cell numbers in
the EVPL model as measured by Cohen's d (Spearman's rank correlation, rs = 0.45, p = 0.16) B. Results of P. aeruginosa
biofilms grown in the EVPL model and treated with 64 µg/mL ciprofloxacin (highest MIC value recorded). Values below the
dashed line were below the limit of detection. Please click here to view a larger version of this figure.
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Figure 2. Total CFU of 8 Staphylococcus aureus CF clinical isolates recovered from the EVPL model following
treatment with linezolid. Each strain was grown on EVPL tissue for 48 h then transferred to linezolid (triangles) for 24 h or
were untreated as a control (circles). All strains were found to be sensitive to linezolid using the standard disk diffusion assay
following EUCAST guidelines30  (zone of inhibition > 21 mm). Data were analyzed using t-tests when appropriate and Mann-
Whitney U tests for non-parametric datasets (P < 0.05). No significant differences between antibiotic treated and untreated
were found for any of the strains. Values below the dashed line were below the limit of detection. A. Results of S. aureus
biofilms in the EVPL model treated with 4 µg/mL linezolid (clinical breakpoint for sensitive/resistant according to EUCAST
classification31 ). B. Results of S. aureus biofilms in the EVPL model treated with 12 µg/mL linezolid (data reproduced from
Sweeney et al23 ). Please click here to view a larger version of this figure.
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Figure 3. Viable Pseudomonas aeruginosa cell counts of the laboratory strain PA14 and 4 CF clinical isolates
recovered from the EVPL model following treatment with increasing concentrations of colistin. Each strain was grown
on EVPL tissue for 48 h then exposed to colistin for 18 h. The MIC determined in standard cation-adjusted MHB medium is
shown in brackets next to each strain name. The vertical lines show the MBEC value determined in MHB (solid) and SCFM
(dashed), with the exception of SED6, in which the value was the same in both media. The unfilled data points represent the
lowest concentration of colistin tested that resulted in ≥ 3-log10 reduction in CFU/lungcompared to the untreated samples (0
µg/mL colistin) (data reproduced from Sweeney et al26 ). Please click here to view a larger version of this figure.
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Figure 4. Representative viable Pseudomonas aeruginosa cell counts from a time course of growth on the EVPL
model over 24 h, and subsequent treatment with 64 µg/mL meropenem. The laboratory strain P. aeruginosa PA14 and
3 CF clinical isolates were grown on EVPL tissue for the time shown on the x-axis, then transferred to meropenem (triangles)
for 24 h or left untreated as a control (circles). The CFU/lung was then determined. The MIC determined in cation-adjusted
MHB medium is shown in brackets next to each strain name. Please click here to view a larger version of this figure.
 
Figure 5. Representative viable Staphylococcus aureus cell counts following growth on the EVPL model then
treated with 5 µg/mL flucloxacillin over a 24 h time course. The control strain ATCC29213 and two CF clinical isolates
were grown on EVPL tissue for 48 h then transferred to flucloxacillin (triangles) or left untreated as a control (circles) for 4
h and 24 h, before CFU/lung was determined (data reproduced from Sweeney et al23 ). Please click here to view a larger
version of this figure.
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Figure S1.  Please click here to download this figure.
Table S1.  Please click here to download this table.
Discussion
The ex vivo lung model is high throughput and inexpensive
and, because it uses post-consumer waste from the meat
industry, it presents no ethical concerns. It is designed to
mimic chronically-infected human CF airways better than
currently available, in vitro AST platforms. Results presented
here show that it may more accurately predict antibiotic
susceptibility under these circumstances.
Critical steps in the protocol, that will ensure, reliable and
reproducible results include the following:
1. Use consistent time and storage methods between
slaughter, collection, and processing of lung samples.
It is important to use lungs as soon as possible after
slaughter and to keep the potential for contamination
to a minimum. Differences in the ability of experimental
cultures to grow in lungs if they are not as fresh as
possible have been observed.
2. Maintaining sterility in the production of SCFM and
dissection of lung pieces is essential. Healthy lungs are
not sterile and so the presence of commensal bacteria
may reflect a 'natural' environment for chronic infection.
Nevertheless, as previously noted, bacterial interactions
within multispecies populations may alter results and
susceptibility to antibiotics, so contamination should be
avoided and lungs should be sterilized before use. We
advocate the use of UV sterilization, as it does not appear
to cause changes tin tissue integrity and, if necessary,
additional antibiotic washes. However, antibiotics should
be used with caution, as they may influence results
by introducing selective pressures and may alter gene
expression in test bacterial populations.
3. Use mock-infected, negative control tissue samples
and cell count plates grown on a non-selective, rich
medium to highlight the growth of any contaminant or
commensal bacteria that have not been removed during
sterilization. This is essential to mitigate for any impact
of these bacteria on AST. It is also helpful to produce
duplicate, selective agar, cell count plates specific to the
organism of interest, as duplicate plates speed up colony
identification and cell enumeration.
4. Conduct pilot experiments when first using the model and
when using it with new strains or genotype of bacteria to
assess biofilm CFU variations between tissue sections,
allowing the selection of optimal experimental sample
sizes (e.g., how many replicate tissue sections to acquire
from how many replicate lungs) through the use of power
calculations.
5. The assay uses a non-standardized inoculum, as this
allows rapid inoculation after 48 hours of incubation
and the formation of relatively consistent biofilms loads
(especially for P. aeruginosa). To assay antibacterial
efficacy in early biofilm growth stages, consider
inoculating with a standardized CFU of colony-
grown bacteria suspended in ASM. We do not
recommend inoculating with planktonic bacteria: early
pilot experiments showed that this leads to acute,
invasive growth not reliable biofilm formation.
This protocol produces a robust prototype model for use
with P. aeruginosa, with a great potential for development
for use with S. aureus, but it does have some limitations
that will need to be addressed for certain applications in
the future. Tissue was inoculated from single colonies to
allow the development of clonal populations. The results
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show that, for P. aeruginosa, this has little impact on cell
numbers at 48 h. However, greater variability in bacterial
load was observed for S. aureus and, given that different
bacteria may grow differently within the model, a standardized
starting inoculum and rigorous production of tissue samples of
identical size and weight may be dependent on the organism
of study. There may also be differences between labs due to
differences in precise dissection/infection techniques or local
pig breed/landrace. To assess the reproducibility of bacterial
populations for individual implementations of the model, we
suggest the use of repeatability calculations as part of the
statistical analysis of results25  and the use of repeatability/
power calculations based on pilot experiments to calculate the
optimal sample size for their use in final experiments.
One of the key advantages of EVPL over traditional plate
assays is that, rather than testing for bacteria growing
planktonically or on abiotic surfaces, it allows for the spatial
structuring of bacterial biofilms within a host environment
and with cell differentiation. This has important implications
for considering the impact of physiochemical and nutrient
gradients on the activity of antimicrobial agents as well as
the delivery and availability of active therapies at different
microenvironments within a chronic infection and cell-cell
interaction between bacteria. This latter point is particularly
significant, as multispecies infections are routinely observed
in CF and are becoming increasingly important to infections
associated with other respiratory conditions, such as asthma
and chronic obstructive pulmonary disease. There is potential
to develop this model for the AST for individualized patient
sputum sampling in the clinical diagnostics. An analogous trial
is already underway using a wound-mimicking in vitro model
for growth and AST of debrided biofilm from chronic wounds
(Southwest Regional Wound Care Center in Lubbock, Texas,
Dr. R. Wolcott).
Furthermore, the model uses post-mortem tissue, so the
influence of the host immune response on antibiotic
susceptibility is limited. Current in vitro models also do not
account for host immune responses, so we do not see this as
a barrier to the future use of the model in AST applications.
However, the immune response is taken into consideration
when pharmacokinetic and pharmacodynamic parameters
and antibiotic dosing guidelines are determined. Although
our studies have shown evidence of residual immune cells
and responses within the tissue23  (and S. Azimi, personal
communication), this is a prime area for further optimization
and development of the model if a greater match to in vivo
conditions is desired.
Providing more clinically valid AST for CF will help meet a key
recommendation of the UK Health, Social Care Act 2008 that
"procedures should be in place to ensure prudent prescribing
and antimicrobial stewardship." We believe the EVPL is an
ideal candidate model to help meet this need.
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